Cell kill kinetics of an antineoplastic nucleoside, 1-(2-deoxy-2-methylene-β-D-erythro-pentofuranosyl)cytosine

Biochemical Pharmacology

Volumn 52, Issue 8, 1996, Pages 1279-1285

  Ono, Takashi ^a   Fujii, Akihiro ^a   Yamagami, Keiji ^a   Hosoya, Masahiro ^a   Okumoto, Takeki ^a   Sakata, Shinji ^b   Matsuda, Akira ^c   Sasaki, Takuma ^d  

^a Yoshitomi Pharmaceutical Industries Ltd   (Japan)

^b YAMASA CORPORATION   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

ara C; cell cycle; cell kill kinetics; cytotoxicity; DMDC

Indexed keywords

1 (2 DEOXY 2 METHYLENE BETA D ERYTHRO PENTOFURANOSYL)CYTOSINE; 1 (2 DEOXY 2 METHYLENE BETA D ERYTHRO PENTOFURANOSYL)CYTOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYTARABINE; CYTARABINE TRIPHOSPHATE; DNA; DRUG METABOLITE; NUCLEOSIDE DERIVATIVE; PROTEIN; RADIOISOTOPE; RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL KILLING; CELL LEVEL; CELL SYNCHRONIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; KINETICS; MACROMOLECULE; MELANOMA CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0030601827     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00483-2     Document Type: Article

References (19)

1. 1. Takenuki K, Matsuda A, Ueda T, Sasaki T, Fujii A and Yamagami K, Design, synthesis, and antineoplastic activity of 2′-deoxy-2′-methylidenecytidine. J Med Chem 31: 1063-1064, 1988.
2. 2. Matsuda A, Takenuki K, Tanaka M, Sasaki T and Ueda T, Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2′-deoxy-2′-methylidenecytidine (DMDC) and its derivatives. J Med Chem 34: 812-819, 1991.
3. 3. Yamagami K, Fujii A, Arita M, Okumoto T, Sakata S, Matsuda A, Ueda T and Sasaki T, Antitumor activity of 2′-deoxy-2′-methylidenecytidine, a new 2′-deoxycytidine derivative. Cancer Res 51:2319-2323, 1991.
4. 4. Robins MJ, Samano V, Zhang W, Balzarini J, De Clercq E, Borchardt RT, Lee Y and Yuan C-S, Nucleic acid related compounds. 74. Synthesis and biological activity of 2′ (and 3′)-deoxy-2′(and 3′)-methylenenucleoside analogues that function as mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase and/or ribonucleotide reductase. J Med Chem 35: 2283-2293, 1992.
5. 5. Lin T-S, Luo M-Z, Liu M-C, Clarke-Katzenburg RH, Cheng Y-C, Prusoff WH, Mancini WR, Birnbaum GI, Gabe EJ and Giziewicz J, Synthesis and anticancer and antiviral activities of various 2′-and 3′-methylidene-substituted nucleoside analogues and crystal structure of 2′-deoxy-2′-methylidenecytidine hydrocbloride. J Med Chem 34: 2607-2615, 1991.
6. 6. Matsuda A, Azuma A, Nakajima Y, Takenuki K, Dan A, Iino T, Yoshimura Y, Minakawa N, Tanaka M and Sasaki T, Design of new types of antitumor nucleosides: The synthesis and antitumor activity of 2′-deoxy-(2′-C-substituted)cytidines. In: Nucleosides and Nucleotides as Antitumor and Antiviral Agents (Eds. Chu CK and Baker DC), pp. 1-22. Plenum Press, New York, 1993.
7. 7. Wakabayashi S, Taniguchi M, Tokuhisa T, Tomioka H and Okamoto S, Cytotoxic T lymphocytes induced by syngeneic mouse melanoma cells recognize human melanomas. Nature 294: 748-750, 1981.
8. 8. Pedrali-Noy G, Spadari S, Miller-Faures A, Miller AOA, Kruppa J and Koch G, Synchronization of HeLa cell cultures by inhibition of DNA polymerase a with aphidicolin. Nucleic Acids Res 8: 377-387, 1980.
9. 9. Hershko A, Mamont P, Shields R and Tomkins GM, "Pleiotypic response." Nature New Biol 232: 206-211, 1971.
10. 10. Graham FL and Whitmore GF, The effect of 1-β-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 30: 2627-2635, 1970.
11. 11. Bhuyan BK, Fraser TJ, Gray LG, Kuentzel SL and Neil GL, Cell-kill kinetics of several S-phase-specific drugs. Cancer Res 33: 888-894, 1973.
12. 12. Yataganas X, Strife A, Perez A and Clarkson BD, Microfluorimetric evaluation of cell kill kinetics with 1-β-D-arabinofuranosylcytosine. Cancer Res 34: 2795-2806, 1974.
13. 13. Fried J, Perez AG, Doblin JM and Clarkson BD, Cytotoxic and cytokinetic effects of 1-β-D-arabinofuranosylcytosine, daunorubicin, and 6-thioguanine on HeLa cells in culture. Cancer Res 41: 1127-1132, 1981.
14. 14. Bhuyan BK, Scheldt LG and Fraser TJ, Cell cycle phase specificity of antitumor agents. Cancer Res 32: 398-407, 1972.
15. 15. Pallavicini MG, Cytosine arabinoside: Molecular, pharmacokinetic and cytokinetic considerations. In: Cell Cycle Effect of Drugs (Ed. Dethlefsen LA), pp. 136-169. Pergamon Press, New York, 1986.
16. 16. Darzynkiewicz Z, Cell growth and division cycle. In: Cell Cycle Effect of Drugs (Ed. Dethlefsen LA), pp. 1-43. Pergamon Press, New York, 1986.
17. 17. Smets LA and Homan-Blok J, S1-phase cells of the leukemic cell cycle sensitive to 1-β-D-arabinofuranosylcytosine at a high-dose level. Cancer Res 45: 3113-3117, 1985.
18. 18. Hennequin C, Giocanti N, Balosso J and Favaudon V, Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 54: 1720-1728, 1994.
19. 19. Gandhi V and Plunkett W, Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48: 329-334, 1988.